Clinical Trials

A Phase II Trial of PET-Directed Therapy using AVD (doxorubicin, vinblastine, and dacarbazine) plus Brentuximab Vedotin Induction Chemotherapy, with or without Brentuximab Vedotin plus Nivolumab, Followed by Nivolumab Consolidation for Patients with Previously Untreated Non-bulky Limited Stage Hodgkin Lymphoma


Study ID
ACCRU-LY-1601

NCT Number
NCT03233347 (Click on the NCT number for more information about the trial)

Research Study Number
2018-0051

Principle Investigator
Dr. Tatyana Feldman

Phase
II

Sponsor
ACCRU


Other protocol defined inclusion/exclusion criteria could apply If you are a physician and would like more details about this study, please contact us at JTCCResearch@HackensackMeridian.org

Apply Now